As different levels of BCR-ABL expression have been observed not only in CML cell lines but also in patients (55–57), the two mutated CML cell lines used in this study may inadequately represent the broader CML patient population. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.